Therakind
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, including paediatric and geriatric populations. They excel in innovating new formulations and drug delivery systems, notably their proprietary DriDose® intranasal device, which aims to improve medicine adherence and ease of use. The company has successfully developed and marketed three products, with a strong pipeline of innovative medicines and drug delivery solutions designed to meet the specific needs of challenging patient groups.
Industries
Nr. of Employees
small (1-50)
Therakind
London, England, United Kingdom, Europe
Products
Jylamvo
2 mg/mL methotrexate oral solution developed as a palatable liquid formulation for patients with swallowing difficulties and for paediatric dosing.
Buccolam
Pre‑filled oromucosal midazolam syringe for emergency treatment of prolonged acute convulsive seizures in infants, children and adolescents; company provided regulatory strategy and clinical sponsorship for the product.
Ayendi
Nasal diamorphine spray developed for acute severe pain management in children and adolescents; regulatory strategy and clinical development were provided during approval and post‑authorisation studies.
Dry‑powder intranasal unit‑dose device
Single‑use pre‑filled dry‑powder nasal device intended for simple self‑administration or caregiver use; propellant‑free and designed to deliver a measured dose without patient inhalation or coordination.
Dry‑powder intranasal multi‑dose cartridge system
Reusable device body with disposable pre‑filled cartridges or nosepieces enabling multiple doses, configurable dose ranges and reduced single‑use waste compared with fully disposable devices.
Nosatron (preclinical nasal delivery system)
Reusable preclinical delivery device and disposable carriers for animal model testing featuring adjustable air volume/pressure, multiple adaptors, and semi‑automated powder filling.
Jylamvo
2 mg/mL methotrexate oral solution developed as a palatable liquid formulation for patients with swallowing difficulties and for paediatric dosing.
Buccolam
Pre‑filled oromucosal midazolam syringe for emergency treatment of prolonged acute convulsive seizures in infants, children and adolescents; company provided regulatory strategy and clinical sponsorship for the product.
Ayendi
Nasal diamorphine spray developed for acute severe pain management in children and adolescents; regulatory strategy and clinical development were provided during approval and post‑authorisation studies.
Dry‑powder intranasal unit‑dose device
Single‑use pre‑filled dry‑powder nasal device intended for simple self‑administration or caregiver use; propellant‑free and designed to deliver a measured dose without patient inhalation or coordination.
Dry‑powder intranasal multi‑dose cartridge system
Reusable device body with disposable pre‑filled cartridges or nosepieces enabling multiple doses, configurable dose ranges and reduced single‑use waste compared with fully disposable devices.
Nosatron (preclinical nasal delivery system)
Reusable preclinical delivery device and disposable carriers for animal model testing featuring adjustable air volume/pressure, multiple adaptors, and semi‑automated powder filling.
Services
Feasibility / proof‑of‑concept programme for intranasal candidates
Reformulation, analytical characterisation and compatibility testing of partner drug candidates with dry‑powder intranasal delivery formats to generate de‑risking data prior to development.
Formulation development for nasal powders and oral liquids
Laboratory formulation services for dry‑powder intranasal products, peptide and vaccine candidates, and age‑appropriate oral liquid formulations.
Clinical trial design and management
End‑to‑end planning and operational management of multi‑site clinical trials, including studies in emergency and hospital settings and post‑authorisation safety monitoring.
Regulatory strategy and submission support
Regulatory planning, dossier preparation and liaison with authorities across EMA, FDA and national agencies, including support for paediatric regulatory pathways.
Partnerships, licensing and commercialisation support
Business development services including identification and negotiation of distribution, licensing and out‑licensing agreements and support for market roll‑out.
Feasibility / proof‑of‑concept programme for intranasal candidates
Reformulation, analytical characterisation and compatibility testing of partner drug candidates with dry‑powder intranasal delivery formats to generate de‑risking data prior to development.
Formulation development for nasal powders and oral liquids
Laboratory formulation services for dry‑powder intranasal products, peptide and vaccine candidates, and age‑appropriate oral liquid formulations.
Clinical trial design and management
End‑to‑end planning and operational management of multi‑site clinical trials, including studies in emergency and hospital settings and post‑authorisation safety monitoring.
Regulatory strategy and submission support
Regulatory planning, dossier preparation and liaison with authorities across EMA, FDA and national agencies, including support for paediatric regulatory pathways.
Partnerships, licensing and commercialisation support
Business development services including identification and negotiation of distribution, licensing and out‑licensing agreements and support for market roll‑out.
Expertise Areas
- Intranasal drug delivery
- Formulation development for powders and oral liquids
- Clinical trial design and operational management
- Regulatory strategy and submissions (including paediatric pathways)
Key Technologies
- Dry‑powder intranasal delivery
- Pre‑filled unit‑dose delivery devices
- Reusable device bodies with disposable cartridges/nosepieces
- Preclinical delivery adaptors and adjustable nozzles